Lacour, Jean-Philippe

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 2,110

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology

Dermatology and Skin DiseasesAsthma and respiratory diseases

Cited by 638

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

Simpson, E. L., Lacour, J. ‐., Spelman, L., Galimberti, R., Eichenfield, L. F., Bissonnette, R., King, B. A., Thyssen, J. P., Silverberg, J. I., Bieber, T., et al. (2020) · British Journal of Dermatology

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 396

The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from ASSURE ‐ CSU

Maurer, M., Abuzakouk, M., Bérard, F., Canonica, W., Oude Elberink, H., Giménez‐Arnau, A., Grattan, C., Hollis, K., Knulst, A., Lacour, J. ‐., et al. (2017) · Allergy

Urticaria and Related ConditionsMast cells and histamine

Cited by 383

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

Ständer, S., Yosipovitch, G., Legat, F. J., Lacour, J.-P., Paul, C., Narbutt, J., Bieber, T., Misery, L., Wollenberg, A., Reich, A., et al. (2020) · New England Journal of Medicine

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 281

Senescent cells develop a parp-1 and nuclear factor-κB-associated secretome (PNAS).

Ohanna, M., Giuliano, S., Bonet, C., Imbert, V., Hofman, V., Zangari, J., Bille, K., Robert, C., Bressac-de Paillerets, B., Hofman, P., et al. (2011) · Genes & Development

Telomeres, Telomerase, and SenescenceNF-κB Signaling Pathways

Cited by 267

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Faiz, S., Giovannelli, J., Podevin, C., Jachiet, M., Bouaziz, J.-D., Reguiai, Z., Nosbaum, A., Lasek, A., Ferrier le Bouedec, M.-C., Du Thanh, A., et al. (2019) · Journal of the American Academy of Dermatology

Dermatology and Skin DiseasesAsthma and respiratory diseases

Cited by 210

Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells

Cheli, Y., Giuliano, S., Fenouille, N., Allegra, M., Hofman, V, Hofman, P., Bahadoran, P., Lacour, J.-P., Tartare-Deckert, S., Bertolotto, C., et al. (2012) · Oncogene

Melanoma and MAPK PathwaysCancer Cells and Metastasis

Cited by 185

Anatomical mapping of Merkel cells in normal human adult epidermis

LACOUR, J. P., DUBOIS, D., PISANI, A., & ORTONNE, J. P. (1991) · British Journal of Dermatology

Polyomavirus and related diseasesTactile and Sensory Interactions

Cited by 112

Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype

Ohanna, M., Cheli, Y., Bonet, C., Bonazzi, V. F., Allegra, M., Giuliano, S., Bille, K., Bahadoran, P., Giacchero, D., Lacour, J. P., et al. (2013) · Oncotarget

Telomeres, Telomerase, and SenescenceMelanoma and MAPK Pathways

Cited by 78